Headlines about Endologix (NASDAQ:ELGX) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Endologix earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave news articles about the medical instruments supplier an impact score of 46.6046338904954 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the media stories that may have effected Accern’s analysis:
- Reviewing Endologix (ELGX) & Its Competitors (americanbankingnews.com)
- Head-To-Head Contrast: Endologix (ELGX) and Its Rivals (americanbankingnews.com)
- Endologix (ELGX) Now Covered by Piper Jaffray Companies (americanbankingnews.com)
- Analyzing Endologix (ELGX) & The Competition (americanbankingnews.com)
- Financial Review: Endologix (ELGX) versus Its Rivals (americanbankingnews.com)
A number of equities analysts recently commented on ELGX shares. ValuEngine cut shares of Endologix from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Royal Bank of Canada decreased their target price on shares of Endologix from $5.00 to $4.00 and set a “sector perform” rating on the stock in a research report on Wednesday, November 8th. Stifel Nicolaus set a $6.00 target price on shares of Endologix and gave the stock a “hold” rating in a research report on Friday, October 6th. Canaccord Genuity reiterated a “hold” rating and issued a $5.00 target price on shares of Endologix in a research report on Wednesday, September 27th. Finally, Piper Jaffray Companies reiterated an “overweight” rating on shares of Endologix in a research report on Tuesday. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $5.41.
Endologix Company Profile
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
What are top analysts saying about Endologix? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Endologix and related companies.